VNDA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Vanda Pharmaceuticals Inc (VNDA) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows promising growth potential due to its recent FDA approval for BYSANTI, strong analyst support, and a pipeline of near-commercial-ready assets. Despite insider selling and negative net income, the company's revenue growth and product pipeline make it a solid long-term investment.
The technical indicators are moderately positive. The MACD histogram is above 0 and positively contracting, suggesting a potential upward trend. The RSI is neutral at 44.362, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot point of 7.256, with key resistance at 7.649 and support at 6.862.
FDA approval of BYSANTI, a first-line therapy for bipolar I disorder and schizophrenia.
Analysts have raised price targets, with the highest being $24, citing significant growth potential in the psychiatry franchise.
The company has a promising pipeline, including Nereus, which has a $1B market opportunity.
Insider selling has increased significantly (972.59% over the last month).
The company reported a negative net income of -$141.19M in Q4 2025, despite revenue growth.
Gross margin dropped slightly by -1.74% YoY.
In Q4 2025, revenue increased by 7.58% YoY to $57.22M. However, net income was -$141.19M, up 2774.33% YoY, and EPS was -2.39, up 2887.50% YoY. Gross margin slightly declined to 90.24%.
Analysts are bullish on VNDA. Truist, B. Riley, and H.C. Wainwright have all issued Buy ratings with price targets ranging from $17 to $24, citing strong growth potential in the psychiatry franchise and a promising pipeline of near-commercial-ready assets.
